Targeting the urokinase plasminogen activator pathway inhibits pancreatic cancer progression

被引：0
|
作者：
Hosen, S. M. Z. [1 ,2 ]
Haar, J. [1 ,2 ]
Xu, Z. [1 ,2 ]
Perera, C. [1 ,2 ]
Mekapogu, A. R. [1 ,2 ]
Pang, T. C. Y. [1 ,2 ]
Pothula, S. [1 ,2 ]
Goldstein, D. [1 ]
Pirola, R. [1 ]
Wilson, J. [1 ]
Buckley, B. J. [3 ,4 ,5 ]
Ranson, M. [3 ,4 ,5 ]
Apte, M. [1 ,2 ]
机构：
[1] Univ New South Wales, Pancreat Res Grp, South Western Sydney Clin Sch, Fac Med, Sydney, NSW, Australia
[2] Ingham Inst Appl Med Res, Sydney, NSW, Australia
[3] Univ Wollongong, Mol Horizons, Fac Sci Med & Hlth, Wollongong, NSW, Australia
[4] Univ Wollongong, Sch Chem & Mol Biosci, Fac Sci Med & Hlth, Wollongong, NSW, Australia
[5] Illawarra Hlth & Med Res Inst, Wollongong, NSW, Australia
来源：
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2021年 / 36卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
219
引用
收藏
页码：25 / 26
页数：2
相关论文
共 50 条
  • [21] CFTR suppresses tumor progression through miR-193b targeting urokinase plasminogen activator (uPA) in prostate cancer
    Xie, C.
    Jiang, X. H.
    Zhang, J. T.
    Sun, T. T.
    Dong, J. D.
    Sanders, A. J.
    Diao, R. Y.
    Wang, Y.
    Fok, K. L.
    Tsang, L. L.
    Yu, M. K.
    Zhang, X. H.
    Chung, Y. W.
    Ye, L.
    Zhao, M. Y.
    Guo, J. H.
    Xiao, Z. J.
    Lan, H. Y.
    Ng, C. F.
    Lau, K. M.
    Cai, Z. M.
    Jiang, W. G.
    Chan, H. C.
    ONCOGENE, 2013, 32 (18) : 2282 - 2291
  • [22] The role of urokinase plasminogen activator receptor in HNcSCC progression and metastasis
    Minaei, Elahe
    Mueller, Simon A.
    Thind, Amarinder Singh
    Ashford, Bruce
    Perry, Jay
    Clark, Jonathan
    Gupta, Ruta
    Ranson, Marie
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 34 - 34
  • [23] Targeting the Urokinase Plasminogen Activator System in Combination With Chemotherapy Halts Primary Tumor Growth and Eliminates Metastasis in Advanced Pancreatic Cancer
    不详
    PANCREAS, 2022, 51 (07) : 858 - 859
  • [24] Exogenous Urokinase Inhibits Proteasomal Degradation of Its Cognate Urokinase Plasminogen Activator Receptor
    Zhu, Ran
    Liu, Ting-Wei
    Liu, Fan
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [25] Urokinase plasminogen activator's affect on cancer progression in non-small cell lung cancer
    Kutz, Craig
    Canine, Jenny
    Provost, Joseph J.
    Wallert, Mark
    FASEB JOURNAL, 2009, 23
  • [26] THE UROKINASE PLASMINOGEN-ACTIVATOR PATHWAY AS A NOVEL MECHANISM OF TUMOR TARGETING AND CELL-MEMBRANE TRAVERSAL
    JANKUN, J
    JOURNAL OF CELLULAR BIOCHEMISTRY, 1993, : 33 - 33
  • [27] Inhibition of invasion and metastasis in oral cancer by targeting urokinase-type plasminogen activator receptor
    Nozaki, S
    Endo, Y
    Nakahara, H
    Yoshizawa, K
    Hashiba, Y
    Kawashiri, S
    Tanaka, A
    Nakagawa, K
    Matsuoka, Y
    Kogo, M
    Yamamoto, E
    ORAL ONCOLOGY, 2005, 41 (10) : 971 - 977
  • [28] Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic cancer is correlated with shorter survival
    Friess, H
    Cantero, D
    Zimmermann, A
    Korc, M
    Buchler, MW
    GASTROENTEROLOGY, 1996, 110 (04) : A389 - A389
  • [29] Urokinase plasminogen activator gene deficiency inhibits fracture cartilage remodeling
    Nicoleta L. Popa
    Jon E. Wergedal
    K.-H. William Lau
    Subburaman Mohan
    Charles H. Rundle
    Journal of Bone and Mineral Metabolism, 2014, 32 : 124 - 135
  • [30] Imaging Active Urokinase Plasminogen Activator in Prostate Cancer
    LeBeau, Aaron M.
    Sevillano, Natalia
    Markham, Kate
    Winter, Michael B.
    Murphy, Stephanie T.
    Hostetter, Daniel R.
    West, James
    Lowman, Henry
    Craik, Charles S.
    VanBrocklin, Henry F.
    CANCER RESEARCH, 2015, 75 (07) : 1225 - 1235
12345